Sign in
Advances in the treatment of Raynaud's phenomenon
Journal article   Open access  Peer reviewed

Advances in the treatment of Raynaud's phenomenon

Terri L Levien
Vascular health and risk management, Vol.6(1), pp.167-177
03/24/2010
Handle:
https://hdl.handle.net/2376/107992
PMID: 20448801
url
https://doi.org/10.2147/VHRM.S4551View
Published (Version of record) Open

Abstract

Raynaud Disease - drug therapy Vasodilator Agents - therapeutic use Humans Calcium Channel Blockers - therapeutic use Serotonin Uptake Inhibitors - therapeutic use Serotonin Antagonists - therapeutic use Botulinum Toxins, Type A - therapeutic use Antioxidants - therapeutic use Bosentan Sulfonamides - therapeutic use Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Iloprost - therapeutic use Phosphodiesterase 5 Inhibitors - therapeutic use Endothelin Receptor Antagonists

Details